Otolaryngol Head Neck Surg
Use of GLP‑1 agonists linked to fewer sinus surgery revisions
A retrospective cohort analysis using the TriNetX network evaluated adults with chronic rhinosinusitis with nasal polyps (CRSwNP) and obesity who had undergone prior functional endoscopic sinus surgery (FESS), comparing outcomes between those prescribed GLP‑1 receptor agonists (RAs) and matched controls. Among 1,391 patients in each group, GLP‑1 RA users had lower rates of revision FESS at both 1 year (risk ratio [RR], 0.64) and 5 years (RR, 0.60). They also had reduced first‑time biologic prescriptions at 5 years (RR, 0.72). These observational findings suggest GLP‑1 RAs may be associated with improved long‑term postoperative outcomes, although prospective studies are needed.
Clinical takeaway: Consider whether GLP‑1 RAs may provide added postoperative benefit for appropriate patients recovering from sinus surgery, especially when metabolic comorbidities are present.
Source:
Hoying D, et al. (2025, December 7). Otolaryngol Head Neck Surg. Assessing the Impact of GLP-1R Agonists in Post-sinus Surgery Management. https://pubmed.ncbi.nlm.nih.gov/41353729/